GET DAILY SIGNALSAlnylam Pharmaceuticals (ALNY): A Closer Look at the RNAi Therapeutics Leader
Key Takeaways
- ALNY is the ticker for Alnylam Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company and pioneer in RNA interference (RNAi) therapeutics.
- The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
- Alnylam's marketed medicines include AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO, with partner-commercialized products such as Leqvio.
- Its revenue is driven primarily by product sales, led by AMVUTTRA, with additional collaboration and royalty income.
- Investors follow ALNY for its leadership in RNAi science, a deep clinical pipeline, and expansion beyond rare diseases into larger cardio-metabolic markets.
Company Background
Alnylam Pharmaceuticals, Inc. (ALNY) has played a key role in transforming a Nobel Prize-winning discovery into a new category of medicines. The firm focuses on RNA interference (RNAi), a natural process that silences specific genes to block production of proteins linked to disease. As a commercial-stage company with several approved treatments and an extensive pipeline, Alnylam holds a unique place in the biotech sector and draws attention from investors interested in genetic medicine approaches.
Founding and Operations
Alnylam was established in 2002 to develop RNAi as a therapeutic platform, building on the 2006 Nobel Prize in Physiology or Medicine. Headquartered in Cambridge, Massachusetts, the company is led by Chief Executive Officer Yvonne Greenstreet. Its first major milestone came in 2018 when ONPATTRO (patisiran) received approval as the world's initial RNAi therapeutic, shifting the organization from pure research toward a fully integrated commercial business.
The core model involves discovering, developing, manufacturing, and commercializing RNAi-based treatments. These therapies use small interfering RNA (siRNA) molecules to break down messenger RNA (mRNA) before harmful proteins form, acting earlier in the disease process than many conventional drugs. Proprietary delivery methods, such as the GalNAc platform, help target cells effectively, especially in the liver. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Revenue comes mainly from net product sales, along with collaboration and royalty income. Marketed products include AMVUTTRA (vutrisiran) and ONPATTRO (patisiran) for transthyretin-mediated (ATTR) amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1. Royalties flow from partner-sold therapies like Leqvio (inclisiran) from Novartis and Qfitlia from Sanofi, with additional partnerships involving Regeneron and Roche.
Alnylam is viewed as the frontrunner in RNAi therapeutics thanks to a strong intellectual-property position and a pipeline covering cardio-metabolic disease, neuroscience, and other areas. Its commercial reach spans the United States, Europe, and additional international markets.
Why This Stock Draws Investor Attention
Investors track ALNY for its established role in a proven yet still emerging treatment modality. RNAi can offer durable, convenient options, with several drugs requiring only occasional injections. This supports better patient adherence and steady revenue streams for ongoing conditions.
A major growth factor is the move beyond rare diseases into broader populations. AMVUTTRA’s approval for ATTR amyloidosis with cardiomyopathy (ATTR-CM) has meaningfully expanded the potential market, while pipeline candidates address hypertension, Alzheimer’s disease, and metabolic issues. The “platform effect”—applying one validated technology across multiple diseases—remains central to the company’s longer-term strategy and financial outlook.
Risks Worth Considering
Like other biopharmaceutical firms, Alnylam encounters notable risks. Revenue is still heavily tied to AMVUTTRA, so performance, pricing, and competition in that product can significantly affect results. The ATTR amyloidosis and cardiology spaces include rival therapies that may limit future growth.
Clinical and regulatory hurdles also apply: pipeline programs could fall short in trials or fail to gain approvals. Complex manufacturing and delivery technologies add operational challenges, while international activities face pricing and reimbursement pressures, including government reforms. Royalty obligations to partners may further influence margins as sales increase.
Using Tickeron’s AI Screener for Deeper Analysis
In my own research process, Tickeron’s AI Screener has become a helpful resource for screening stocks and ETFs based on technical indicators, fundamentals, volatility, trends, AI-generated signals, and customizable filters. It allows me to quickly identify ideas that align with specific strategies and compare opportunities across industries. This kind of tool supports a more structured approach when evaluating names like ALNY alongside peers.
Conclusion
Alnylam Pharmaceuticals has established itself as the company that moved RNAi therapeutics from scientific concept to approved, revenue-generating medicines. Its validated platform, expanding product set, and broad pipeline create a distinctive profile in biotechnology. Concentration risk and clinical uncertainties persist, yet the ability to apply one technology across many diseases keeps Alnylam relevant for investors following innovation in genetic medicine.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALNY's Stochastic Oscillator sits in oversold zone for 5 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +1.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALNY advanced for three days, in 216 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
ALNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALNY as a result. In 58 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for ALNY turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 32 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.
ALNY moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALNY crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
The Aroon Indicator for ALNY entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. ALNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.409) is normal, around the industry mean (3.498). P/E Ratio (26.566) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.330) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.911) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics based on RNA interference
Industry Biotechnology
Advertisement